The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: Reduced relapse risk in female to male transplants

Bone Marrow Transplantation

Volumn 35, Issue 6, 2005, Pages 609-617

  Gahrton, Gosta ^a   Iacobelli, S ^b   Apperley, J ^c   Bandini, G ^d   Bjorkstrand B ^a   Blade J ^e   Boiron, J M ^f   Cavo, M ^d   Cornelissen, J ^g   Corradini, P ^h   Kroger N ⁱ   Ljungman, P ^a   Michallet, M ^j   Russell, N H ^k   Samson, D ^c   Schattenberg, A ^l   Sirohi, B ^m   Verdonck, L F ⁿ   Volin, L ^o   Zander, A ⁱ   Niederwieser, D ^p   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e HOSPITAL CLÍNIC   (Spain)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j EDOUARD HERRIOT HOSPITAL   (France)

^k NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Royal Marsden Hospital   (United Kingdom)

ⁿ AZ Utrecht   (Netherlands)

^o HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^p UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

Allogeneic stem cell transplantation; Multiple myeloma

Indexed keywords

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; SEX DIFFERENCE; SIBLING; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; RISK; SEX FACTORS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 20144389643     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704861     Document Type: Article

References (37)

1. Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
2. Sporn JR, McIntyre OR. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin Oncol 1986; 13: 318-325.
3. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
4. Blade J, San Miguel JF, Fontanillas M et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001; 2: 272-278.
5. Barlogie B, Alexanian R, Dicke KA et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-872.
6. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
8. Gahrton G, Ringden O, Lonnqvist B et al. Bone marrow transplantation in three patients with multiple myeloma. Acta Med Scand 1986; 219: 523-527.
9. Tura S, Cavo M, Baccarani M et al. Bone marrow transplantation in multiple myeloma. Scand J Haematol 1986; 36 176-179.
10. Gahrton G, Tura S, Ljungman P et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991; 325: 1267-1273.
11. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
12. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1322.
13. Corradini P, Cavo M, Lokhorst H et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927-1929.
14. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
15. Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 2001; 38: 243-249.
16. Sasazuki T, Juji T, Morishima Y et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177-1185.
17. Gahrton G, Tura S, Ljungman P et al. An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. European Group for Blood and Marrow Transplantation. Stem Cells 1995; 13 (Suppl 2): 122-125.
18. Zwaan FE, Hermans J, Barrett AJ et al. Bone marrow transplantation for acute nonlymphoblastic leukaemia: a survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.). Br J Haematol 1984; 56: 645-653.
19. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
20. Vogt MH, de Paus RA, Voogt PJ et al. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood 2000; 95: 1100-1105.
21. Vogt MH, Goulmy E, Kloosterboer FM et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 2000; 96: 3126-3132.
22. Vogt MH, van den Muijsenberg JW, Goulmy E et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99: 3027-3032.
23. Spierings E, Vermeulen CJ, Vogt MH et al. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet 2003; 362: 610-615.
24. Randolph SS, Gooley TA, Warren EH et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004; 103: 347-352.
25. Miklos DB, Kim HT, Zorn E et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004; 103: 353-359.
26. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216.
27. Gray R. A class of k-sample tests for comparing the cumulative incidence of competing risk. Ann Statist 1988; 16: 1141-1154.
28. Prentice RL, Kalbfleisch JD, Peterson Jr AV et al. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554.
29. Gooley TA, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
30. Aschan J, Lonnqvist B, Ringden O et al. Graft-versus-myeloma effect. Lancet 1996; 348: 346.
31. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031-3037.
32. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87 1196-1198.
33. Gratwohl A HJ, Niederwieser D, van Biezen A et al. Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J 2001; 2: 363-370.
34. James E, Chai JG, Dewchand H et al. Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood 2003; 102: 388-393.
35. Verdijk RM, Kloosterman A, Pool J et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 2004; 103: 1961-1964.
36. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
37. WMDA. Donor Registries Annual Report 2002, Vol 1, 6th edn. WMDA: Leiden, The Netherlands, 2003.